Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1050 of 6351
-
Can proton radiation spare tonsil cancer patients from harsh side effects?
Disease control Recruiting nowIn this trial, patients with early squamous cell carcinoma of the tonsil with clinical stage T1-2 (p16-positive or p16-negative) N0-1 (p16-positive)/N0-N2b (p16-negative) according to American Joint Committee on Cancer (AJCC) 8th edition, aimed for unimodal and ipsilateral treatm…
Sponsor: Lund University Hospital • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Lab-Made enzyme tame a rare genetic disorder?
Disease control Recruiting nowResearchers are looking for a better way to treat people who have classical homocystinuria (HCU), a rare condition that is passed down by parents (or "genetic condition"). It is caused by changes in the cystathionine beta-synthase (or "CBS") gene and prevents an enzyme from worki…
Phase 1/2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Gene therapy cocktail shows promise for tough mesothelioma
Disease control CompletedThis study will evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma (MPM) who have failed a minimum of 1 treatment regimen…
Phase 3 • Sponsor: Ferring Ventures Limited • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to fight rare, aggressive breast cancer
Disease control OngoingThis phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repa…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental combo targets Chemo-Resistant cancers
Disease control OngoingThe open label, first-in-human, phase 1, dose escalation component in refractory solid tumors has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was determined to be 1.5mg/kg. The Expansion Phase of this study is currently enrolling subjects with …
Phase 1/2 • Sponsor: Precision Biologics, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo attack on stubborn myeloma shows promise in early trial
Disease control OngoingThis phase II trial studies how well daratumumab, bortezomib, and dexamethasone followed by daratumumab, ixazomib, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not response to treatment (refractory). Immunotherapy with monoclo…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a blood thinner or a device prevent strokes after a brain bleed?
Disease control Recruiting nowRandomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH). There…
Phase 3 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can a tailored antibiotic regimen shorten endocarditis treatment without risk?
Disease control OngoingExisting guidelines recommend a duration of antibiotic treatment of endocarditis of 4-6 weeks one or more types of intravenously administered antibiotics. The long hospitalization increases several risks for the patient, including mental strain and increased loss of function. Fur…
Sponsor: Herlev Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a cherry fruit tame metabolic syndrome?
Disease control CompletedThis randomized, double-blind, placebo-controlled, parallel-group study evaluated the effects of six-month oral supplementation with Cornus mas fruit lyophilizate in patients with metabolic syndrome. Participants were assigned to receive either 8 g of Cornus mas fruit lyophilizat…
Sponsor: Wroclaw Medical University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can zapping cancer spots with Super-Precise radiation delay the disease?
Disease control Recruiting nowThis study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could a common blood pressure drug help fight prostate cancer?
Disease control Stopped earlyThis randomized pilot clinical trial studies how well propranolol hydrochloride works in treating patients with prostate cancer who are undergoing surgery. When stressed, the body makes a molecule that may prevent tumor cells from dying, and propranolol hydrochloride may affect t…
Phase 2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for rare genetic cancers? drug targets POLE/POLD1 mutations
Disease control Recruiting nowThe purpose of this study is to evaluate the response of toripalimab (JS001), a PD1 antibody, in participants with POLE or POLD-mutated and non microsatellite instability (non-MSI-H) advanced solid cancers.
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo aims to stop breast cancer return after failed chemo
Disease control OngoingThis study will enroll patients who received neoadjuvant therapy for TNBC prior to surgery and did not get pCR. Given the relatively poor prognosis for these patients, this population is considered novel therapeutic as adjuvant treatment. Currently, capecitabine monotherapy could…
Phase 2 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to tame heart sarcoidosis with fewer side effects
Disease control Recruiting nowProspective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hyp…
Phase 3 • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug shows promise in reducing bleeding for hemophilia patients
Disease control OngoingPrimary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: * To characterize the efficacy and long-term efficacy of fitusiran as assessed by the frequency of: * Bleeding episodes * Spontaneous bleeding episodes * Joint bl…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug cocktail aims to outsmart resistant lung cancer
Disease control OngoingThis study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare kidney cancer: drug combo shows promise
Disease control OngoingThis phase II trial studies how well axitinib and nivolumab work in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Axitinib may stop the growth of tumor cells b…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Intense lifestyle overhaul shows promise for new diabetes patients
Disease control OngoingIt is a multicenter, open-label, parallel-group, randomized controlled clinical trial, which is designed to enroll newly diagnosed type 2 diabetes patients with overweight or obesity. The patients are randomized to an intensive diet intervention (intermittent very-low -calorie di…
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
HIV-Positive livers safe for HIV-Positive patients? landmark trial results
Disease control CompletedThe primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug shows promise for stubborn cancers
Disease control OngoingGSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refrac…
Phase 2 • Sponsor: Actuate Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC